Compare · DXCM vs MODD
DXCM vs MODD
Side-by-side comparison of DexCom Inc. (DXCM) and Modular Medical Inc. (MODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 2031.7x MODD ($13.6M).
- Over the past year, DXCM is down 19.6% and MODD is down 88.1% - DXCM leads by 68.5 points.
- MODD has been more active in the news (14 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for MODD).
- Company
- DexCom Inc.
- Modular Medical Inc.
- Price
- $71.54+1.52%
- $2.50-14.82%
- Market cap
- $27.61B
- $13.6M
- 1M return
- +2.57%
- -40.90%
- 1Y return
- -19.62%
- -88.10%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 14
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Modular Medical Inc.
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest MODD
- Modular Medical Announces Formation of Pivot Innovation Council and Appointment of Robert Gabbay, MD, PhD, FACP as Chairman
- Modular Medical and IMO Health Launch Strategic Pilot to Enable Real Time Insulin Pump Patient Identification Into Electronic Health Records
- Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump
- Modular Medical Announces Completion of Research Initiative Indicating Strong Interest in Simpler Insulin Delivery
- SEC Form 4 filed by Director Vos Ellen O'Connor
- SEC Form 4 filed by Director Sheibley Philip Brent
- SEC Form 4 filed by Director Goldberg Jeff D
- Director Felsher Steven G was granted 25 shares, increasing direct ownership by 0.30% to 8,498 units (SEC Form 4)
- Director Volkart Carmen B was granted 110 shares, increasing direct ownership by 14% to 916 units (SEC Form 4)
- Director Desisto Duane M was granted 83 shares, increasing direct ownership by 0.97% to 8,627 units (SEC Form 4)